Advertisement

Topics

Immunotherapy for Bladder Cancer

20:00 EDT 19 Jun 2017 | JAMA

Several weeks after approving avelumab to treat a rare form of skin cancer, the FDA authorized its use for patients with locally advanced or metastatic urothelial cancer who haven’t responded to platinum-based chemotherapy.

Original Article: Immunotherapy for Bladder Cancer

NEXT ARTICLE

More From BioPortfolio on "Immunotherapy for Bladder Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...